|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Sinequa, a recognized leader in the AI-powered search and analytics market, today announced a $23 million Series B funding round led by Jolt Capital and supported by Troismer BVBA, an existing investor. With this new funding, Sinequa will invest in its award-winning AI-powered search and analytics platform that connects knowledge workers in some of the world’s largest organizations with the information, expertise and insights necessary to make information-driven decisions. According to IDC, by 2020 organizations able to analyze enterprise content and data assets to deliver actionable information and insights will achieve an extra $430 billion in productivity benefits over their less analytically oriented peers.
HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Almirall. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Almirall.
IRVING, Texas, Nov. 15, 2018 /PRNewswire/ -- Thermi®, an Almirall, S.A. company, today announced that it has received a notice of completion to a U.S. Food and Drug Administration (FDA) inquiry on products used in "vaginal rejuvenation" procedures. Thermi received an "It has come to our attention" notice from the FDA on July 24, 2018 regarding specific claims about the company's ThermiVa® device in the United States. ThermiVa, a non-ablative radiofrequency application, has been cleared by the FDA for use in dermatological and general surgical procedures for electrocoagulation and hemostasis.